Press releaseGlobe Newswire
ArriVent BioPharma
AVBP · NASDAQ
$18.85+$0.91 (+5.07%)TodayMarket closed ·
Prev close $17.94
Latest news
- Press releasePRNewswire
ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky
- Press releaseBusiness Wire
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
- Press releasePRNewswire
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
- Press releasePRNewswire
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
- NewsVandana Singh
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
- NewsAvi Kapoor
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
- NewsAvi Kapoor
Dow Jumps 200 Points; US Trade Deficit Widens In August
- NewsAvi Kapoor
Vicor, AXT And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Press releaseBusiness Wire
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
- Press releasePRNewswire
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
- Press releasePRNewswire
$207B Market Shift: The Race for Fast Track Approval in Oncology
- Press releasePRNewswire
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
- News
ArriVent Doses First Patient In Phase 3 ALPACCA Trial Of Firmonertinib For The Treatment Of EGFR-Mutant NSCLC
- Press releaseGlobe Newswire
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
- Press releasePRNewswire
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
- NewsAvi Kapoor
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
- NewsVandana Singh
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside
- NewsAvi Kapoor
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.